首页> 美国卫生研究院文献>other >Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study

【2h】

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study

机译：一项非甾类抗炎药在接受培美曲塞加卡铂治疗的肺癌患者中引起严重的血液学毒性：一项回顾性队列研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeAs the major toxicity induced by pemetrexed plus carboplatin is severe hematologic toxicities, the aim of this study was to determine the risk factors for severe hematologic toxicities in lung cancer patients.

机译：目的由于培美曲塞加卡铂引起的主要毒性是严重的血液学毒性，因此本研究的目的是确定肺癌患者发生严重血液学毒性的危险因素。

著录项

期刊名称 other
作者
Hitoshi Kawazoe; Akiko Yano; Yuri Ishida; Kenshi Takechi; Hitoshi Katayama; Ryoji Ito; Yoshihiro Yakushijin; Toshihide Moriguchi; Mamoru Tanaka; Akihiro Tanaka; Hiroaki Araki;
展开▼
作者单位

展开▼
年(卷),期 -1(12),2
年度 -1
页码 e0171066
总页数 10
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study [J] . Chen Lei, San Antonio Belen, Yan Yu, Current medical research and opinion . 2017,第5期

机译：用Pemetrexed Plus Carboplatin治疗的非小细胞肺癌患者的安全谱：真实世界的回顾，观测，队列研究
2. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 [J] . Kanazawa Kenya, Yokouchi Hiroshi, Wang Xintao, Cancer chemotherapy and pharmacology. . 2014,第6期

机译：卡铂和培美曲塞作为一线化疗治疗非鳞状非小细胞肺癌的第二阶段试验，以及与培美曲塞代谢相关的功效/毒性和遗传多态性之间的相关性：北海道肺癌临床研究组试验（HOT）0902
3. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. [J] . Patel JD, Bonomi P, Socinski MA, Clinical lung cancer . 2009,第4期

机译：突破性研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐单抗的随机，开放标签III期研究，然后进行培美曲塞/贝伐单抗与紫杉醇/卡铂/贝伐单抗的维持治疗，对IIIB或IV期非鳞状非IV期患者进行贝伐珠单抗治疗-小细胞肺癌。
4. LIPID PROFILING OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) ON PROSTATE CANCER CELL LINES WITH TOF-SIMS AND DESI-MS [C] . Danielle J. McDougall, Emrys Jones, Claire Hart, International Mass Spectrometry Conference . 2018

机译：具有TOF-SIMS和DESI-MS的前列腺癌细胞系上的非甾体抗炎药（NSAID）的脂质分析
5. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: A population-based nested-case control study. [D] . Mahmud, Salaheddin. 2009

机译：非甾体类抗炎药的使用和前列腺癌的风险：一项基于人群的嵌套病例对照研究。
6. PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Ralph G. Zinner, Coleman K. Obasaju, David R. Spigel, -1

机译：代名词：晚期非鳞状非小细胞肺癌患者一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗+贝伐珠单抗一线治疗的随机开放标签III期研究
7. Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. [O] . Hitoshi Kawazoe, Akiko Yano, Yuri Ishida, 2017

机译：非甾体类抗炎药在接受培美曲塞加卡铂治疗的肺癌患者中引起严重的血液学毒性：一项回顾性队列研究。

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study

摘要

著录项

相似文献

相关主题

期刊订阅